Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships

Rhea-AI Summary

Lunai Bioworks (NASDAQ:RENB) announced progress in its biomarker discovery preclinical program for Parkinson's Disease through its subsidiary BioSymetrics. The company's Augusta Platform leverages AI and machine learning to identify distinct patient subtypes and uncover novel treatment pathways.

The initiative addresses a significant market opportunity, with Parkinson's affecting over 10 million people globally and expected to double by 2050. BioSymetrics' Phenograph knowledge graph enables patient stratification and therapeutic hypothesis matching, supported by an NIH STTR grant. The company is actively seeking pharmaceutical partnerships to advance its biomarker-driven programs.

Positive

• Targeting large and growing market with over 10 million Parkinson's patients globally
• Received competitive NIH STTR grant validation
• Proprietary Augusta Platform and Phenograph technology for patient stratification
• Positioning for pharmaceutical partnerships to accelerate development

Negative

• Early-stage preclinical program with no immediate revenue potential
• Operating in highly competitive AI drug discovery space
• Significant time and resources required for drug development

NEW YORK CITY, NEW YORK / ACCESS Newswire / September 25, 2025 / Lunai Bioworks Inc. (NASDAQ:RENB), an AI-powered drug discovery company and parent of wholly owned subsidiary BioSymetrics, today announced advancement of its biomarker discovery preclinical program in Parkinson's Disease. The initiative leverages BioSymetrics' proprietary Augusta Platform to unlock novel treatment pathways in one of the world's fastest-growing neurological markets. The company is actively positioning the program for strategic partnership with pharmaceutical collaborators.

Parkinson's Disease affects over 10 million people globally, with incidence expected to double by 2050. Nearly one million individuals in the US alone live with the disease, a figure projected to rise sharply due to an aging population. This expanding patient population represents a significant unmet need and a compelling opportunity for therapeutic innovation.

BioSymetrics' approach centers on phenogrouping, identifying distinct patient subtypes using its Phenograph knowledge graph and machine learning engine. This enables the company to stratify patients with greater precision, uncover hidden disease mechanisms, and match subgroups with targeted therapeutic hypotheses. The strategy was recently spotlighted in a Michael J. Fox Foundation webinar hosted by BioSymetrics.

BioSymetrics has developed algorithms and digital biomarkers that can be applied for diagnosis, patient stratification, and treatment response prediction, as well as to accelerate therapeutic development. Its applied AI projects have used large-scale datasets to refine Parkinson's subtypes for precision medicine applications. As Lunai's wholly owned subsidiary, BioSymetrics' Parkinson's initiative spans drug target discovery, validation, and clinical study optimization.

"Our goal is to translate computational insights into actionable biology," said Dr. Gabe Musso, Chief Scientific Officer of BioSymetrics. "By integrating multimodal data and refining phenotypic subtypes, we're laying the groundwork for biomarker-driven programs that can be rapidly advanced through pharma collaboration."

BioSymetrics also contributes open-source repositories and collaborative pipelines for multimodal Parkinson's data analysis, reinforcing Lunai's commitment to both research and clinical progress. The Parkinson's initiative builds on Lunai's broader mission to integrate AI-powered analytics with translational research, accelerating diagnosis and drug discovery across complex neurological disorders.

The company's differentiated model, which combines proprietary neurotoxicity datasets, experimental screening, and machine learning, has earned validation through a competitive STTR grant from the National Institutes of Health (NIH), supporting its translational pipeline.

About Lunai Bioworks

Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. Through its wholly owned subsidiary BioSymetrics, Lunai integrates proprietary datasets, advanced machine learning, and ethical innovation to accelerate therapeutic breakthroughs while safeguarding society from emerging threats.

Investor Contact
David Weinstein
Chief Executive Officer
investors@renovaro.com
www.renovarogroup.com

SOURCE: Lunai Bioworks Inc.

View the original press release on ACCESS Newswire

FAQ

What is Lunai Bioworks' (NASDAQ:RENB) approach to Parkinson's Disease research?

Lunai Bioworks uses its Augusta Platform and Phenograph knowledge graph to identify distinct patient subtypes, develop digital biomarkers, and match patient subgroups with targeted therapeutic hypotheses.

How many people are affected by Parkinson's Disease globally according to Lunai Bioworks?

According to Lunai Bioworks, over 10 million people globally are affected by Parkinson's Disease, with nearly one million in the US alone. This number is expected to double by 2050.

What validation has Lunai Bioworks (RENB) received for its technology?

Lunai Bioworks has received validation through a competitive STTR grant from the National Institutes of Health (NIH) supporting its translational pipeline.

What is BioSymetrics' role in Lunai Bioworks' Parkinson's research?

BioSymetrics, a wholly owned subsidiary of Lunai Bioworks, develops algorithms and digital biomarkers for diagnosis, patient stratification, and treatment response prediction in Parkinson's Disease.

What are Lunai Bioworks' (NASDAQ:RENB) plans for partnerships?

Lunai Bioworks is actively positioning its biomarker discovery program for strategic partnerships with pharmaceutical collaborators to advance its research and development efforts.